This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
== Osteopathies, chondropathies, and acquired musculoskeletal deformities (730–739) == 730 Osteomyelitis, periostitis, and other infections involving bone 731 Osteitis deformans and osteopathies associated with other disorders 732 Osteochondropathies 732.7 Osteochondritis dissecans 733 Other disorders of bone and cartilage 733.0 Osteoporosis 733.1 Pathologic fracture 733.2 Cyst of bone 733.3 Hyperostosis of skull 733.4 Aseptic necrosis of bone 733.5 Osteitis condensans 733.6 Tietze's disease Costochondritis 733.7 Algoneurodystrophy 733.8 Malunion and nonunion of fracture 733.9 Other and unspecified disorders of bone and cartilage 733.90 Disorder of bone and cartilage, unspecified Osteopenia Ostealgia 733.92 Chondromalacia 734 Flat foot 735 Acquired deformities of toe 735.0 Hallux valgus 735.2 Hallux rigidus 735.4 Hammer toe, other 736 Other acquired deformities of limbs 736.1 Mallet finger 736.2 Other acquired deformities of finger 736.7 Other acquired deformities of ankle and foot 736.8 Acquired deformities of other parts of limbs 736.81 Unequal leg length (acquired) 736.89 Other acquired deformity of other parts of limb Winged scapula 736.9 Acquired deformity, limb, unspec. 737 Curvature of spine 737.1 Kyphosis (acquired) 737.2 Lordosis (acquired) 737.3 Scoliosis 737.9 Kyphosis/scoliosis, unspec.
=== Impregnation === Due to its low viscosity while retaining solvent capacities, supercritical carbon dioxide is also used for impregnation of different raw materials. The biggest industrial application in this field is impregnation of wood with biocides. The big advantage is, that the CO2 can penetrate the complete structure of the board, carrying the active ingredient and therefore fully impregnating it.
This production has been described as also producing "melamine scrap" which is not "pure melamine but impure melamine scrap that is sold more cheaply as the waste product after melamine is produced by chemical and fertilizer factories here." Shandong Mingshui Great Chemical Group, the company reported by The New York Times as producing melamine from coal, produces and sells both urea and melamine but does not list melamine resin as a product. Melamine production in China has increased greatly in recent years and was described as in "serious surplus" in 2006. In the United States Geological Survey 2004 Minerals Survey Yearbook, in a report on worldwide nitrogen production, the author stated that "China continued to plan and construct new ammonia and urea plants using coal gasification technology." The off-gas in production contains large amounts of ammonia (see melamine synthesis). Therefore, melamine production is often integrated into urea production which uses ammonia as feedstock. Crystallization and washing of melamine generates a considerable amount of waste water, which is a pollutant if discharged directly into the environment. The waste water may be concentrated into a solid (1.5-5% of the weight) for easier disposal. The solid may contain approximately 70% melamine, 23% oxytriazines (ammeline, ammelide and cyanuric acid), 0.7% polycondensates (melem, melam and melon). In January 2009, China's Ministry of Industry and Information Technology promulgated draft production permit rules aiming to stem a melamine production glut.
Sources: en.wikipedia.org
==== Uruguay ==== Cider fizz or fizz is a cider variety made by mixing and fermenting various fruit juices other than apple with cider, as ananá fizz (pineapple juice), frutilla fizz (strawberry juice) or durazno fizz (peach juice).
== Binding specificity == The effects of a drug are a result of their binding selectivity with macromolecule properties of an organism, or the affinity with which different ligands bind to a substrate. More specifically, the specificity and selectivity of a ligand to its respective receptor provides researchers the opportunity to isolate and produce specific drug effects through the manipulation of ligand concentrations and receptor densities. Hormones and neurotransmitters are essential endogenous regulatory ligands that affect physiological receptors within an organism. Drugs that act upon these receptors are incredibly selective in order to produce required responses from signaling molecules. Specific binding refers to the binding of a ligand to a receptor, and it is possible that there is more than one specific binding site for one ligand. Non specific binding refers to the binding of a ligand to something other than its designated receptor such as various other receptors, or different types of transporters in the cell membrane. For example, various antagonists can bind to multiple types receptors. In the case of muscarinic antagonists, they can also bind to histamine receptors. Such binding patterns are technically considered specific, as the destination of the ligand is specific to multiple receptors. However, researchers may not be focused on such behaviors compared to other binding factors. Nevertheless, nonspecific binding behavior is very important information to acquire.
==== Russia/Belarus MEU FDP Rule ==== Russia and Belarus are subject to the same restrictions as the military end use/user rule, with more expansive coverage that includes foreign-produced items made using U.S.-origin software or technology, manufactured by plants or major components that are products of the U.S.
Sources: en.wikipedia.org
=== As a neurotransmitter === Glycine is a neurotransmitter in the central nervous system with both inhibitory and excitatory roles. Specifically, it is an agonist at the inhibitory glycine receptor, and a co-agonist along with glutamate at the excitatory NMDA receptor. The glycine receptor is expressed throughout the CNS, but especially in the spinal cord, brainstem, and retina. When glycine receptors are activated, chloride enters the neuron via the receptor, causing an inhibitory postsynaptic potential (IPSP). Strychnine is a strong antagonist at ionotropic glycine receptors, whereas bicuculline is a weak one. Removal of glycine from inhibitory glycinergic synapses is hypothesized to be primarily mediated by glycine transporter 2. This glycine transporter protein is predominantly expressed in neurons, and occurs in the hindbrain and spinal cord. Glycine is a required co-agonist along with glutamate at the excitatory NMDA receptors. That is, these receptors only open their ion channels to let cations into the cell, when both glycine and glutamate are present, while the neuron is already somewhat depolarized. Removal of glycine from NMDA receptor-associated synapses is facilitated by glycine transporter 1, which is hypothesized to co-localize with NMDA receptors in the brain. This glycine transporter protein is predominantly expressed in glial cells, and occurs throughout the brain and spinal cord. The LD50 of glycine is 7930 mg/kg in rats (oral), high concentrations are known to cause marked hyperexcitability and neurotoxicity via the activation of NMDA receptors.
== Function == The tunica externa provides basic structural support to blood vessels. It prevents vessels from expanding too much from internal blood pressure, particularly arteries. It is also relevant in controlling vascular flow in the lungs.
Collagen XVII, previously called BP180, is a transmembrane protein which plays a critical role in maintaining the linkage between the intracellular and the extracellular structural elements involved in epidermal adhesion, identified by Diaz and colleagues in 1990. COL17A1 is the official name of the gene. It encodes the alpha chain of type XVII collagen. Collagen XVII is a transmembrane protein, like collagen XIII, XXIII and XXV. Collagen XVII is a structural component of hemidesmosomes, multiprotein complexes at the dermal-epidermal basement membrane zone that mediate adhesion of keratinocytes to the underlying membrane. It also appears to be a key protein in maintaining the integrity of the corneal epithelium. Mutations in this gene are associated with both generalized atrophic benign and junctional epidermolysis bullosa, as well as recurrent corneal erosions, and expression of this gene is abnormal in various cancers. Two homotrimeric forms of type XVII collagen exist. The full length form is the transmembrane protein. A soluble form, referred to as either ectodomain or LAD-1, is generated by proteolytic processing of the full length form.
The melting point was calculated as 284 ± 50 K (11 ± 50 °C), so that flerovium is probably a liquid at room temperature, although the boiling point was not determined. The electron of a hydrogen-like flerovium ion (Fl113+; remove all but one electron) is expected to move so fast that its mass is 1.79 times that of a stationary electron, due to relativistic effects. (The figures for hydrogen-like lead and tin are expected to be 1.25 and 1.073 respectively.) Flerovium would form weaker metal–metal bonds than lead and would be adsorbed less on surfaces.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.